Explain bad trip care, HPPD risk, and why trial psilocybin is not a microdosing script — CASC communication station

Open. Name time; ask patient and mother top concerns (going mad, addiction medicines, wanting a "treatment dose"). [1]

Explain the bad trip. "Mushrooms contain psilocybin, which strongly affects brain serotonin 5-HT2A systems that help organise perception and sense of self. For some hours that can cause intense visual changes and panic — a bad trip. We keep people safe in a calm environment and support them until it settles; most people do not need long-term antipsychotic from a single episode." [2][1]

Mother's schizophrenia fear. Acknowledge fear; explain temporal link to the drug and settling with abstinence; dual formulation if symptoms returned and persisted; lifelong depot not automatic after one intoxication. [5]

HPPD. "A small number of people get ongoing visual disturbances after the drug has worn off — trailing lights, patterns — that interfere with life. It is uncommon but real. Stopping further psychedelics and getting follow-up helps; tell us if that appears." [3]

Microdosing request. "Some carefully run trials give a measured high dose such as 25 milligrams of pure psilocybin with preparation and therapists present, and they have shown benefits for some people with hard-to-treat depression. That is not the same as buying unknown doses or microdosing at home, and it is not a standard prescription I can write today for recreational products. If depression is the issue, we can discuss proven treatments and, where available, legitimate research pathways — not DIY." [4][1]

Driving and plan. No driving until fully clear; crisis contacts; AOD brief intervention; follow-up if mood, psychosis or visual symptoms; harm reduction (set/setting, adulterants, not using alone, avoiding if psychosis risk). Teach-back. [1][5]

Close. Summarise; check understanding; written advice. [1]